Renovorx, Inc. · NASDAQ:RNXT
Renovorx — Investor Presentation (September 2026)
30 slides from Renovorx's investor presentation, September 2026
Slide 1: Investor Presentation
Investor Presentation NASDAQ | RNXT Delivering therapy where it matters® September 2026 © RenovoRx, Inc. All rights reserved. NASDAQ | RNXT
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation and statements of the Company’s management made in connection therewith contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, i
Slide 3: RenovoRx at a Glance
RenovoRx at a Glance RenovoRx is a commercial-stage targeted oncology platform with two value drivers – 1) FDA-cleared, high margin medical device business scaling rapidly and 2) Fully enrolled pancreatic cancer PH3 trial with survival read-out in '27 Driving adoption of FDA-cleared RenovoCath® acro
Slide 4: Proprietary Trans-Arterial Micro-Perfusion (TAMP) Therapy Platform
Proprietary Trans-Arterial Micro-Perfusion (TAMP) Therapy Platform Enabled by RenovoCath 3 NASDAQ | RNXT
Slide 5: Addressing a Significant Problem in Cancer Treatment
Addressing a Significant Problem in Cancer Treatment Hypervascular tumors are inadequately treated with Hypovascular tumors = major barrier to chemotherapy current therapies treatment success For example, liver tumors are highly vascularized Many tumors, like pancreatic tumors, bile duct tumors, etc
Slide 6: TAMP Improves a Drug's Therapeutic Index
TAMP Improves a Drug’s Therapeutic Index Increases Drug Concentration to Reduces Drug AUC0-t by 43.5% Compared to IV Target Pathological Site by ~100X1 Administration2 Tissue Concentration Gem (mcg/g) Drug Exposure IA vs. IV route 1500 15 Gemcitabine AUC0-t (h*mcg/mL) 1272.83 1250 10 1000 750 5 500
Slide 7: Illustration of TAMP with RenovoCath
6 Illustration of TAMP with NASDAQ | RNXT RenovoCath
Slide 8: Mechanism: Trans-Arterial Micro-Perfusion (TAMP)
Mechanism: Trans-Arterial Micro-Perfusion (TAMP) Mechanism: after vessel isolation, increase in pressure forces drug across the artery wall into the micro-vasculature and into tissue At optimal pressure – tissue pressure is overcome, forcing delivery outside the 70 primary vessel into the tissue 60
Slide 9: Patient and Physician Experience
Patient and Physician Experience RenovoCath Other Treatment Options RenovoCath Patient Experience Other Patient Experience ▪ ~8 treatments over 4 months (2x/month hospital visits) with ▪ Traditional systemic gemcitabine + Abraxane: 12 hospital/clinic disposable device (no implant) visits over 4-mont
Slide 10: RenovoCath: A Drug-Delivery Platform Able to Serve Multiple Markets
RenovoCath: A Drug-Delivery Platform Able to Serve Multiple Markets INITIAL TARGETED ONCOLOGY APPLICATIONS IN UNITED STATES FUTURE $$ GROWTH POTENTIAL 70,000 67,530 Total Addressable Market (TAM) 60,000 Serviceable Addressable Market (SAM)4 Future Expansion Opportunities Could Increase SAM: 50,000 B
Slide 11: Commercial Opportunity: RenovoCath Standalone, FDA-Cleared Drug-Delivery Device
Commercial Opportunity RenovoCath Standalone, FDA-Cleared Drug-Delivery Device 10 NASDAQ | RNXT
Slide 12: High Margin Large Market Opportunity for RenovoCath Standalone Device
High Margin Large Market Opportunity for RenovoCath Standalone Device RenovoCath US Market Opportunity Analogous pressure-mediated delivery $6k-$8.5k/unit1 catheter ASPs Annual average procedures 6 per patient2 Patented Highly Defensible Position Peak annual revenue opportunity $400M3 RenovoRx holds
Slide 13: RenovoCath Go-to-Market Strategy
RenovoCath Go-to-Market Strategy 2026 Commercialization Ramp Builds on 2025 Limited Market Launch, Delivering Record Revenue Growth Concentrated Market: fewer than 200 hospitals treat Go-To-Market Strategy majority of estimated patients where RenovoCath is seeing interest in utilization Broadening a
Slide 14: RenovoCath Commercialization Update (as of 8/12/26)
RenovoCath Commercialization Update (as of 8/12/26) 2025 Commercial Exploration Laid Foundation for 2026 Revenue Growth and Commercialization RenovoCath customers actively treating patients: Customer pipeline 21 cancer centers expansion: 63 total centers have increased commercial Additional RenovoCa
Slide 15: Combination Product Pipeline & Investigator Initiated Trial (IIT) Strategy
Combination Product Pipeline & Investigator Initiated Trial (IIT) Strategy Centers can bill for the TAMP procedure regardless of the agent administered. To generate new data, RenovoRx is conducting the Phase III TIGeR-PaC trial (fully enrolled August 2026) and supports IITs exploring administration
Slide 16: Pivotal Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer
Pivotal Phase III TIGeR-PaC Clinical Trial (NCT03257033) in Locally Advanced Pancreatic Cancer (LAPC) 15 NASDAQ | RNXT
Slide 17: Significant Unmet Need
Significant Unmet Need Three FDA approvals for first line pancreatic cancer in the last 10 years showed minimal Median Overall Survival (OS) benefit and increased toxicity1 Gemcitabine + Abraxane Abraxane 38% Grade 3 Abraxane obtained FDA approval in 2013 on a or Higher Neutropenia and 7-week Median
Slide 18: Potential Market Penetration Based on Modest Efficacy from TIGeR-PaC
Potential Market Penetration Based on Modest Efficacy from TIGeR-PaC Independent interviews suggest oncologists likely to adopt gemcitabine delivered via RenovoCath w/ at least 3–4-month OS benefit and toxicity improvement are met 5 Number of Respondents 4 3 2 1 0 <1 1 month 2 months 3 months 4 mont
Slide 19: TIGeR-PaC Phase III Randomized Trial Design
TIGeR-PaC Phase III Randomized Trial Design Combination Product Trial for TAMP Delivery of Intra-Arterial (IA) Gemcitabine (IAG) via FDA-Cleared RenovoCath in Locally Advanced Pancreatic Cancer (LAPC) Induction Phase 1:1 RANDOMIZATION PHASE 1◦ Endpoint 4-month treatment protocol: standard of care IV
Slide 20: TAMP: 6-Month Median OS Benefit vs. IV Gemcitabine + Abraxane
TAMP (IA Gemcitabine via RenovoCath): 6-Month Median OS Benefit vs. IV (Systemic) Gemcitabine + Abraxane TIGeR-PaC phase III first interim analysis Data on 45 patients randomized INDUCTION RANDOMIZED TREATMENT & FOLLOW-UP s • 23 randomized to RenovoCath plus Gemcitabine • 22 randomized to IV gemcita
Slide 21: TAMP (IA Gem) via RenovoCath: Fewer AEs and SAEs vs IV
TAMP (IA Gem) via RenovoCath: Fewer AEs and SAEs vs IV (systemic) Gemcitabine + Abraxane TIGeR-PaC phase III first interim analysis 65% fewer total AEs and SAEs Fewer AEs in 11/13 categories with greater than 10% in IA vs. IV arm frequency in each arm (All Grades) 300 Adverse Events IV Gem + Pac IA
Slide 22: Post-Marketing Registry Study (RR5) & Support of Investigator-Initiated Trials
Post-Marketing Registry Study (RR5) & Support of Investigator-Initiated Trials (IITs) Evidence-Based Growth Strategy Clinical and Strategic Advancement Objective Participating Clinical Sites ▪ Expand real-world safety and efficacy data of TAMP in patients ▪ University of Vermont Cancer Center – bord
Slide 23: RNXT Financial Highlights
RNXT Financial Highlights Record Q2 2026 Revenue of $909K, up 115% Year-Over-Year RNXT (USD) Daily Performance - 2026 YTD through ▪ Driven by accelerating commercial adoption September 11, 2026 ▪ 1H 2026 revenue: $1.5 million, up 138% over 1H 2025; 3.10 Q2 2026 revenue equaled approximately 83% of f
Slide 24: Experienced Management Team
Experienced Management Team Shaun R. Bagai Richard Stark Chief Executive Officer & Board Member Commercial Advisor Consultant ▪ Innoblative Designs 2 ▪ HeartFlow (>$2B IPO) ▪ Ardian (Acquired for > $900M) ▪ AngioDynamics ▪ Medtronic Vascular ▪ TransVascular (Acquired by Medtronic) Ronald B. Kocak, C
Slide 25: Board of Directors
Board of Directors Ramtin Agah, MD Laurence J. Marton, MD Executive Chairman, Chief Medical Officer, & Founder Director ▪ Interventional Cardiology, El Camino Hospital ▪ Board: Cellsonics, TOMA Biosciences, xCures ▪ Consultant, Abbott Vascular Shaun R. Bagai Una S. Ryan, PhD, OBE Director & Chief Ex
Slide 26: RenovoRx Scientific Advisory Board
RenovoRx Scientific Advisory Board Timothy Donahue, MD Karyn A. Goodman, MD, MS ▪ Director of the UCLA Agi Hirshberg Center for Pancreatic ▪ Professor and Vice Chair of Clinical Research, Department of Diseases Radiation Oncology, Icahn School of Medicine at Mount Sinai ▪ Garry Shandling Chair in Pa
Slide 27: RenovoCath Medical Advisory Board
RenovoCath Medical Advisory Board Nadine Abi-Jaoudeh, MD Mustafa Al-Roubaie, MD ▪ Chief of Interventional Radiology and Director of Clinical ▪ Interventional Radiologist at Moffitt Cancer Center Research in the Department of Radiology at the ▪ Associate Professor of Radiology and Oncologic Sciences
Slide 28: RNXT 2026-2027 Milestones
RNXT 2026-2027 Milestones 2026 2027 Q1 Q2 Q3 Q4 Q1 Q2 Completion of TIGeR-PaC RenovoCath Generates $1.1 Million in 2025 Trial Enrollment in August 2026 Launch of IIT in metatastic Revenue RenovoRxin First Full Reports Final human PK pancreatic cancer Year of Q1-Q3 RenovoCath RenovoRx Reports Record
Slide 29: How Hospitals are Using TAMP with RenovoCath in Oncology Management
How Hospitals are Using TAMP with RenovoCath in Oncology Management* Visit https://ir.renovorx.com/news-events/clinical-news to Learn More NBC News highlighted the potential of RenovoRx's Trans-Arterial Micro-Perfusion (TAMP) therapy platform, designed for targeted drug-delivery via the RenovoCath d
Slide 30: Thank You
Investor Contact: Thank You KCSA Strategic Communications Valter Pinto or Jack Perkins | RenovoRx@KCSA.com +1.212.896.1254 Media Contact: StiR Communications Hannah Williams | Hannah@stir-communications.com +1.803.521.1214 © RenovoRx, Inc. All rights reserved. NASDAQ | RNXT